Literature DB >> 825329

Clinical and endocrine features of hyperprolactinaemic amenorrhoea.

H S Jacobs, S Franks, M A Murray, M G Hull, S J Steele, J D Nabarro.   

Abstract

The clinical, radiological and endocrine findings in thirty-five women with hyperprolactinaemia and amenorrhoea are described. Twelve patients had radiological evidence of a pituitary tumour and six were tested after pituitary ablation. Seventeen patients with hyperprolactinaemia and normal pituitary X-rays were also studied. None was on any drug known to increase prolactin secretion and all patients were euthyroid when tested. Basal serum prolactin concentrations were high in the group with untreated pituitary tumours and in those with normal X-rays. The levels were variable in the post-ablation cases. The increase of prolactin after TRH was subnormal in all of the groups. Serum oestradiol concentrations were low in most patients and nineteen of twenty-one patients tested had no withdrawal bleeding after treatment with a progestogen. Mean serum gonadotrophin concentrations (basal and after LHRH) were normal in twenty-nine patients but subnormal in four post-ablative cases. Anovulatory responses to clomiphene were obtained in nineteen of twenty patients tested. Fifteen patients were treated with bromocriptine; twelve ovulated and eight became pregnant; two not responding had impaired LH and FSH production. Hyperprolactinaemic amenorrhoea is a common disorder with characteristic endocrine features. Galactorrhoea is unusual (30%). Treatment with bromocriptine lowers prolactin concentrations and rapidly repairs the reproductive defect.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 825329     DOI: 10.1111/j.1365-2265.1976.tb01974.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  21 in total

1.  Anovulation and ovulation induction.

Authors:  I Katsikis; M Kita; A Karkanaki; N Prapas; D Panidis
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

2.  Hypothalamic-pituitary-ovarian function in hyperprolactinemic women.

Authors:  P Travaglini; B Ambrosi; P Beck-Peccoz; R Elli; M Rondena; R Bara; G Weber
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

3.  Reversal of severe osteopenia in a patient with hyperprolactinemia treated with bromocriptine.

Authors:  J S Lindberg; F O Kolb; R A Blau; M R Powell
Journal:  West J Med       Date:  1988-09

Review 4.  Prolactin: role in health and disease.

Authors:  D F Horrobin
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

5.  Serum LH increase after estradiol and progesterone administration in hyperprolactinemic women.

Authors:  P Travaglini; R Elli; B Ambrosi; M Ballabio; P Moriondo; G Faglia
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

6.  Prolactinoma: a question of rational treatment.

Authors:  C R Edwards; C M Feek
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-12

Review 7.  Investigation and treatment of amenorrhoea resulting in normal fertility.

Authors:  M G Hull; P E Savage; H S Jacobs
Journal:  Br Med J       Date:  1979-05-12

Review 8.  Use of bromocriptine in hyperprolactinaemic anovulation and related disorders.

Authors:  S Franks
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

9.  Value of bromocriptine in unexplained primary infertility: a double-blind controlled trial.

Authors:  C S Wright; S J Steele; H S Jacobs
Journal:  Br Med J       Date:  1979-04-21

10.  Intrauterine development, feto-placental function and pregnancy outcome after induction of ovulation with bromoergocryptine.

Authors:  M R Clemens; R Göser; E Keller; W Zubke; H Traut; A E Schindler
Journal:  Arch Gynakol       Date:  1978-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.